Filing Flows › Syndax Pharmaceuticals (SNDX) › R&D spending
Syndax Pharmaceuticals (SNDX) R&D spending by quarter
Syndax Pharmaceuticals' R&D spending was $67.5M in Q3 2026 (third quarter 2026), -0.8% from Q2 2026. Over the last 7 quarters it ranged from $56.3M (Q3 2025) to $78.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $67.5M | -0.8% | +20% |
| Q2 2026 | $68.0M | +16% | +9% |
| Q1 2026 | $58.8M | -25% | -5% |
| Q4 2025 | $78.6M | +40% | — |
| Q3 2025 | $56.3M | -10% | — |
| Q2 2025 | $62.2M | +1% | — |
| Q1 2025 | $61.6M | — | — |
Q3 2026 at a glance
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Syndax Pharmaceuticals' R&D spending?
Syndax Pharmaceuticals' R&D spending was $67.5M in Q3 2026 (third quarter 2026), -0.8% from Q2 2026.
How has Syndax Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $56.3M (Q3 2025) to $78.6M (Q4 2025).
Q3 2026 results → · How Syndax Pharmaceuticals makes money →